File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients

TitleQuantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients
Authors
Issue Date2004
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
Blood, 2004, v. 104 n. 1, p. 243-249 How to Cite?
AbstractIn Epstein-Barr-virus (EBV)-positive lymphomas in immunocompetent patients, release of EBV DNA from tumor cells into the plasma might be useful for disease monitoring and prognostication. To test this hypothesis, we quantified serially plasma EBV DNA by quantitative polymerase chain reaction in 39 cases of EBV-positive (natural killer [NK] cell, n = 23; T cell, n = 8; B cell, n = 4; Hodgkin, n = 4) lymphomas. As control, EBV DNA was undetectable in 34 cases of EBV-negative lymphomas at diagnosis and during chemotherapy. In all cases of EBV-positive lymphomas, EBV DNA was detectable (105-1010 copies/mL) at diagnosis. It paralleled the clinical course, with EBV DNA becoming undetectable at remission and remaining elevated in refractory disease. On multivariate analysis, high-presentation EBV DNA (> 7.3 × 10 7 copies/mL) was significantly associated with an inferior overall survival (OS). Subgroup analysis of NK cell lymphomas, the largest cohort in this study, showed that presentation EBV DNA was correlated with disease stage and lactate dehydrogenase. On multivariate analysis, high-presentation EBV DNA (> 6.1 × 107 copies/mL) was significantly associated with an inferior disease-free survival. During treatment, patients with EBV DNA that showed further increases or failed to become undetectable had significantly inferior OS. In EBV-positive lymphomas, plasma EBV DNA is valuable as a tumor biomarker and for prognostication. © 2004 by The American Society of Hematology.
Persistent Identifierhttp://hdl.handle.net/10722/77588
ISSN
2015 Impact Factor: 11.841
2015 SCImago Journal Rankings: 6.395
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_HK
dc.contributor.authorPang, Aen_HK
dc.contributor.authorChoy, Cen_HK
dc.contributor.authorChim, CSen_HK
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2010-09-06T07:33:32Z-
dc.date.available2010-09-06T07:33:32Z-
dc.date.issued2004en_HK
dc.identifier.citationBlood, 2004, v. 104 n. 1, p. 243-249en_HK
dc.identifier.issn0006-4971en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77588-
dc.description.abstractIn Epstein-Barr-virus (EBV)-positive lymphomas in immunocompetent patients, release of EBV DNA from tumor cells into the plasma might be useful for disease monitoring and prognostication. To test this hypothesis, we quantified serially plasma EBV DNA by quantitative polymerase chain reaction in 39 cases of EBV-positive (natural killer [NK] cell, n = 23; T cell, n = 8; B cell, n = 4; Hodgkin, n = 4) lymphomas. As control, EBV DNA was undetectable in 34 cases of EBV-negative lymphomas at diagnosis and during chemotherapy. In all cases of EBV-positive lymphomas, EBV DNA was detectable (105-1010 copies/mL) at diagnosis. It paralleled the clinical course, with EBV DNA becoming undetectable at remission and remaining elevated in refractory disease. On multivariate analysis, high-presentation EBV DNA (> 7.3 × 10 7 copies/mL) was significantly associated with an inferior overall survival (OS). Subgroup analysis of NK cell lymphomas, the largest cohort in this study, showed that presentation EBV DNA was correlated with disease stage and lactate dehydrogenase. On multivariate analysis, high-presentation EBV DNA (> 6.1 × 107 copies/mL) was significantly associated with an inferior disease-free survival. During treatment, patients with EBV DNA that showed further increases or failed to become undetectable had significantly inferior OS. In EBV-positive lymphomas, plasma EBV DNA is valuable as a tumor biomarker and for prognostication. © 2004 by The American Society of Hematology.en_HK
dc.languageengen_HK
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/en_HK
dc.relation.ispartofBlooden_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshCase-Control Studiesen_HK
dc.subject.meshDNA, Viral - blooden_HK
dc.subject.meshEpstein-Barr Virus Infections - immunology - virologyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHerpesvirus 4, Human - geneticsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunocompetenceen_HK
dc.subject.meshImmunosuppression - adverse effects - methodsen_HK
dc.subject.meshKiller Cells, Natural - immunologyen_HK
dc.subject.meshLymphoma, T-Cell - blood - drug therapy - genetics - immunology - virologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshNeoplastic Cells, Circulating - pathologyen_HK
dc.subject.meshPrognosisen_HK
dc.subject.meshProspective Studiesen_HK
dc.subject.meshStem Cell Transplantationen_HK
dc.subject.meshSurvival Rateen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.subject.meshTumor Virus Infections - immunology - virologyen_HK
dc.titleQuantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0006-4971&volume=104&issue=1&spage=243&epage=9&date=2004&atitle=Quantification+of+circulating+Epstein-Barr+virus+(EBV)+DNA+in+the+diagnosis+and+monitoring+of+natural+killer+cell+and+EBV-positive+lymphomas+in+immunocompetent+patientsen_HK
dc.identifier.emailChim, CS:jcschim@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityChim, CS=rp00408en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1182/blood-2003-12-4197en_HK
dc.identifier.pmid15031209-
dc.identifier.scopuseid_2-s2.0-3042712887en_HK
dc.identifier.hkuros88710en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-3042712887&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume104en_HK
dc.identifier.issue1en_HK
dc.identifier.spage243en_HK
dc.identifier.epage249en_HK
dc.identifier.isiWOS:000222307500044-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridPang, A=7007044165en_HK
dc.identifier.scopusauthoridChoy, C=7202840937en_HK
dc.identifier.scopusauthoridChim, CS=7004597253en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats